PE20090808A1 - Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina - Google Patents

Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina

Info

Publication number
PE20090808A1
PE20090808A1 PE2008000616A PE2008000616A PE20090808A1 PE 20090808 A1 PE20090808 A1 PE 20090808A1 PE 2008000616 A PE2008000616 A PE 2008000616A PE 2008000616 A PE2008000616 A PE 2008000616A PE 20090808 A1 PE20090808 A1 PE 20090808A1
Authority
PE
Peru
Prior art keywords
phenoxy
peaks
spectrum
imidazol
chloro
Prior art date
Application number
PE2008000616A
Other languages
English (en)
Spanish (es)
Inventor
Anitha Hari
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of PE20090808A1 publication Critical patent/PE20090808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
PE2008000616A 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina PE20090808A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
PE20090808A1 true PE20090808A1 (es) 2009-06-27

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000616A PE20090808A1 (es) 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina

Country Status (11)

Country Link
US (2) US7884219B2 (cg-RX-API-DMAC7.html)
EP (1) EP2144883A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010523559A (cg-RX-API-DMAC7.html)
AR (1) AR065896A1 (cg-RX-API-DMAC7.html)
CA (1) CA2681864A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000987A1 (cg-RX-API-DMAC7.html)
PA (1) PA8775601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20090808A1 (cg-RX-API-DMAC7.html)
TW (1) TW200900384A (cg-RX-API-DMAC7.html)
UY (1) UY31004A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008123914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
KR20150064743A (ko) * 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2005000295A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態

Also Published As

Publication number Publication date
TW200900384A (en) 2009-01-01
US7884219B2 (en) 2011-02-08
JP2010523559A (ja) 2010-07-15
AR065896A1 (es) 2009-07-08
EP2144883A1 (en) 2010-01-20
UY31004A1 (es) 2008-11-28
WO2008123914A1 (en) 2008-10-16
CL2008000987A1 (es) 2008-08-08
CA2681864A1 (en) 2008-10-16
US8372988B2 (en) 2013-02-12
US20110166361A1 (en) 2011-07-07
PA8775601A1 (es) 2009-04-23
US20080249316A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
PE20090808A1 (es) Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina
BRPI0917675A2 (pt) compostos orgânicos para cura de ferida
EP1883448A4 (en) NEW PORTABLE ELECTROCHEMICAL DEVICE FOR HEALING DOUBLE ACTION INJURY
UY29505A1 (es) Forma cristalina de 1-cloro-4-(b(beta)-d-glucopiranos-1-il)-2-(4-((s)-tetrahidrofuran-3-iloxi)-bencil)-benceno, un método para su preparación y el uso del mismo para preparar medicamentos.
EA201190171A1 (ru) Профилированный ключ для цилиндрового замка
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
UA104852C2 (uk) Привідний валок для плоских пасів
PE20130591A1 (es) Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI0812481A2 (pt) Composição aquosa, processo para a fabricação da composição aquosa, uso da composição aquosa, e, processo para a produção de epicloridrina
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
EP2380118A4 (en) Method for monitoring and ranking web visitors and soliciting higher ranked visitors to engage in live assistance
BRPI0816904A2 (pt) Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BR112013013696A2 (pt) método para preparar uma levedura industrial, levedura industrial e uso na produção de etanol a partir de pelo menos uma pentose
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
BRPI0823256A2 (pt) Uso de sacarose como substrato para produção fermentativa de 1,2-propanodiol
BRPI0719908A2 (pt) Forma cristalina, composto, uso de composto, formulação farmacêutica, método de tratamento de uma condição, e, processos para a produção de um composto cristalino e para a cristalização de um composto.
BRPI1008340A2 (pt) forma cristalina, composição farmacêutica, processos para fabricar uma composição farmacêutica e uma forma, uso da forma cristalina, e, método para tratar uma condição de doença
BRPI0720077A2 (pt) Formas de dosagem em microemulsão de valsartan e métodos para a produção das mesmas
WO2013182998A3 (en) Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes
BRPI0810773A2 (pt) Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
BRPI0822509A2 (pt) Fluoroalquilóxi alcanos, processo para sua produção e seus usos

Legal Events

Date Code Title Description
FX Voluntary withdrawal